Literature DB >> 1842181

Patterns of recurrence after pelvic exenteration for colorectal adenocarcinoma.

G H Hafner1, L Herrera, N J Petrelli.   

Abstract

We performed a retrospective review of 68 patients who underwent pelvic exenteration for colorectal adenocarcinoma. Forty-seven patients had surgery for primary disease and 21 for recurrence. Clinical recurrence developed in 30 (44%) of 68 patients overall. Of these, 17 (57%) developed locoregional disease only as their first recurrence. This included nine (56%) of 16 patients with primary disease and eight (57%) of 14 patients with recurrent disease. Clinical recurrence developed in 16 (34%) of 47 patients with primary disease and 14 (66%) of 21 patients with recurrent disease. The overall 5-year survival rates were 43% and 20%, respectively. We conclude that locoregional recurrence remains a significant problem for primary or recurrent colorectal carcinoma even after radical pelvic surgery.

Entities:  

Mesh:

Year:  1991        PMID: 1842181     DOI: 10.1001/archsurg.1991.01410360084013

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

1.  Morbidity and outcome of pelvic exenteration in locally advanced pelvic malignancies.

Authors:  Rajaraman Ramamurthy; Amudhan Duraipandian
Journal:  Indian J Surg Oncol       Date:  2012-07-18

2.  Patterns of recurrence following pelvic exenteration and external radiotherapy for locally advanced primary rectal adenocarcinoma.

Authors:  P Luna-Perez; S Delgado; S Labastida; N Ortiz; D Rodriguez; L Herrera
Journal:  Ann Surg Oncol       Date:  1996-11       Impact factor: 5.344

3.  Intraoperative photodynamic therapy as an adjunct to surgery for recurrent rectal cancer.

Authors:  S P Harlow; M Rodriguez-Bigas; T Mang; N J Petrelli
Journal:  Ann Surg Oncol       Date:  1995-05       Impact factor: 5.344

4.  Retrospective review of pelvic malignancies undergoing total pelvic exenteration.

Authors:  Maureen P Kuhrt; Ravi J Chokshi; David Arrese; Edward W Martin
Journal:  World J Surg Oncol       Date:  2012-06-15       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.